Summary
0.76 0.01(1.37%)10/04/2024
Veru Inc (VERU)
Veru Inc (VERU)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.26 | -0.74 | -14.60 | -19.73 | -7.90 | 3.28 | -64.12 | -86.29 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.76 | |
| Open | 0.77 | |
| High | 0.78 | |
| Low | 0.76 | |
| Volume | 222,330 | |
| Change | 0.01 | |
| Change % | 1.26 | |
| Avg Volume (20 Days) | 390,751 | |
| Volume/Avg Volume (20 Days) Ratio | 0.57 | |
| 52 Week Range | 0.36 - 1.92 | |
| Price vs 52 Week High | -60.19% | |
| Price vs 52 Week Low | 112.31% | |
| Range | -0.13 | |
| Gap Up/Down | -0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 114 | |
| EBIDTA | -75,073,144 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 3.05 | |
| Book Value | 0.3530 | |
| Earnings Per Share | -0.7000 | |
| EPS Estimate Current Quarter | -0.0500 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.2700 | |
| EPS Estimate Next Year | -0.3000 | |
| Diluted EPS (TTM) | -0.7000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -4.1112 | |
| Return on asset (TTM) | -0.5109 | |
| Return on equity (TTM) | -1.2457 | |
| Revenue TTM | 15,929,890 | |
| Revenue per share TTM | 0.1770 | |
| Quarterly Revenue Growth (YOY) | -0.1460 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 30,591,388 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 117.6471 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.2834 | |
| Revenue Enterprise Value | 12.2201 | |
| EBITDA Enterprise Value | -3.2346 | |
| Shares | ||
| Shares Outstanding | 146,380,992 | |
| Shares Float | 104,404,917 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 14.11 | |
| Institutions (%) | 46.26 | |
09/11 08:30 EST - globenewswire.com
Veru to Present at the 2024 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present a corporate update with a focus on the progress of Veru's Phase 2b clinical development program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM – 2:25 PM Eastern Time.
Veru to Present at the 2024 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present a corporate update with a focus on the progress of Veru's Phase 2b clinical development program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM – 2:25 PM Eastern Time.
08/10 08:39 EST - seekingalpha.com
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Gary Nachman - Raymond James Leland Gershell - Oppenheimer Yi Chen - H.C.
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Gary Nachman - Raymond James Leland Gershell - Oppenheimer Yi Chen - H.C.
08/08 08:46 EST - zacks.com
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.
08/08 06:30 EST - globenewswire.com
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected January 2025--
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected January 2025--
08/01 08:30 EST - globenewswire.com
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and to provide a business update.
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and to provide a business update.
07/29 08:30 EST - globenewswire.com
Veru to Participate in the BTIG Virtual Biotechnology Conference
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in one-on-one meetings with investors at the BTIG Virtual Biotechnology Conference on August 5th, 2024.
Veru to Participate in the BTIG Virtual Biotechnology Conference
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in one-on-one meetings with investors at the BTIG Virtual Biotechnology Conference on August 5th, 2024.
07/02 08:30 EST - globenewswire.com
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts.
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts.
06/24 08:30 EST - globenewswire.com
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.
06/18 16:05 EST - globenewswire.com
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that its Annual Meeting of Shareholders scheduled for today (Annual Meeting) was convened and adjourned without any business being conducted due to lack of a required quorum.
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that its Annual Meeting of Shareholders scheduled for today (Annual Meeting) was convened and adjourned without any business being conducted due to lack of a required quorum.
06/17 16:45 EST - globenewswire.com
Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remind shareholders to vote in connection with the Company's upcoming annual meeting of shareholders, to be held on Tuesday, June 18, 2024, at 9:00 AM ET. Shareholders are advised to vote their shares in advance of the proxy voting deadline of tomorrow, Tuesday, June 18, 2024, at 9:00 AM ET.
Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remind shareholders to vote in connection with the Company's upcoming annual meeting of shareholders, to be held on Tuesday, June 18, 2024, at 9:00 AM ET. Shareholders are advised to vote their shares in advance of the proxy voting deadline of tomorrow, Tuesday, June 18, 2024, at 9:00 AM ET.
06/10 08:30 EST - globenewswire.com
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.
05/22 08:30 EST - globenewswire.com
Veru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru's Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am – 11:25 am ET.
Veru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru's Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am – 11:25 am ET.
05/15 08:30 EST - globenewswire.com
Veru Announces Steven B. Heymsfield M.D.
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company's Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss.
Veru Announces Steven B. Heymsfield M.D.
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company's Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss.
05/14 08:30 EST - globenewswire.com
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer, will be a Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week, taking place May 21-23, 2024, in Tel Aviv, Israel.
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer, will be a Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week, taking place May 21-23, 2024, in Tel Aviv, Israel.
05/08 06:30 EST - globenewswire.com
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise--
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise--
05/02 08:30 EST - globenewswire.com
Veru to Present at the GLP-1 Based Therapeutics Summit
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.
Veru to Present at the GLP-1 Based Therapeutics Summit
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.
05/01 08:30 EST - globenewswire.com
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update.
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update.
04/30 10:56 EST - zacks.com
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Veru Inc. (VERU) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VERU's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Veru Inc. (VERU) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VERU's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
04/30 08:30 EST - globenewswire.com
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 --
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 --
04/25 08:30 EST - globenewswire.com
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.